Clinical trials: First Line Treatment
Advanced Colorectal Cancer
Efficacy, Safety and Exploratory Clinical Study of Bevacizumab Combined With Oxaliplatin and TAS-102 in First-line Treatment of Advanced Colorectal Cancer
This study is a single-arm, prospective, open-label observational clinical study to evaluate the efficacy and safety of Bevacizumab combined with Oxaliplatin and TAS-102 in patients with advanced unresectable rectal cancer.
- Trial name
- NCT05364489
- Testing
- Bevacizumab combined with Oxaliplatin and TAS-102
- Volunteers
- 20 people
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
Gastric Cancer
Evaluate the Efficacy of Maintenance Treatment With Capecitabine Plus Apatinib in Advanced Gastric Cancer
This is a multicenter, randomized, controlled trial to evaluate the efficacy and safety of Maintenance Treatment with Capecitabine plus Apatinib, Apatinib and Observation after First-line XELOX/SOX chemotherapy for Patients with…
- Trial name
- NCT03598348
- Testing
- Apatinib+Capecitabine, Apatinib
- Where
- China
- Volunteers
- 288 people
- Sponsor
- Huazhong University of Science and Technology
Head and Neck Cancer, Head and Neck Neoplasms
Enoblituzumab Plus Retifanlimab or Tebotelimab in Head and Neck Cancer
This is a Phase 2 study of enoblituzumab combined with either retifanlimab or tebotelimab administered as first-line treatment to patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
- Conditions
- Head and Neck Cancer, Head and Neck Neoplasms, Head and Neck Squamous Cell Carcinoma
- Trial name
- NCT04634825
- Testing
- Enoblituzumab, Retifanlimab, Tebotelimab
- Where
- 42 sites in United States, Australia and 5 more
- Volunteers
- 62 people
- Sponsor
- MacroGenics
HIV
Second-line Treatment of HIV-1 With Ritonavir Boosted Atazanavir or Darunavir With an Optimized NRTI Backbone
The purpose of this study is to determine the proportion of subjects with HIV-1 RNA < 50 c/mL at Week 48 in patients who failed their first line therapy containing a non-nucleoside reverse transcriptase inhibitor (NNRTI) or an…
- Trial name
- SUPPRESS (NCT01605084)
- Testing
- Atazanavir, Darunavir, Ritonavir
- Where
- 14 sites in United States
- Sponsor
- Bristol-Myers Squibb
Metastatic Colorectal Cancer
First-line FOLFOXIRI Plus Bevacizumab in BRAF Mutant Metastatic Colorectal Cancer
The purpose of this study is to prospectively verify if FOLFOXIRI plus bevacizumab as first-line treatment could be considered a promising approach to improve the outcome of BRAF mutant metastatic colorectal cancer patients
- Trial name
- NCT01437618
- Testing
- FOLFOXIRI plus bevacizumab
- Where
- Italy
- Volunteers
- 15 people
- Sponsor
- Azienda Ospedaliero, Universitaria Pisana
Gastric Adenocarcinoma
Dose-dense Biweekly Docetaxel Combined With 5-fluorouracil as First-line Treatment in Advanced Gastric Cancer
This is an open-label, phase II study to evaluate the efficacy and safety of biweekly docetaxel and DeGramont regimen on unresectable gastric adenocarcinoma in the first-line therapy.
- Trial name
- DaeMon (NCT01567618)
- Testing
- Docetaxel, Fluorouracil
- Where
- China
- Volunteers
- 39 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
Non-small Cell Lung Cancer
Aumolertinib with or Without Chemotherapy As 1st Line Treatment in Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Sensitizing EGFR Mutations
To assess the efficacy and safety of Aumolertinib plus chemotherapy versus Aumolertinib alone as first-line treatment in locally advanced or metastatic non-small cell lung cancer (NSCLC) with sensitizing epidermal growth factor…
- Trial name
- NCT04923906
- Testing
- Aumolertinib
- Where
- China
- Volunteers
- 624 people
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Gastroesophageal Junction Adenocarcinoma, Gastric Adenocarcinoma
ASKB589 in Combination With CAPOX and PD-1 Inhibitor in Patients With Advanced or Metastatic GC/GEJ Adenocarcinoma
This study is a multicenter, randomized, double-blind, standard-of-care controlled phase III clinical study conducted in China. The purpose of this study is to evaluate the efficacy of ASKB589 plus CAPOX and PD-1 inhibitor…
- Trial name
- NCT06206733
- Testing
- ASKB589, Oxaliplatin, Capecitabine
- Where
- China
- Volunteers
- 780 people
- Sponsor
- AskGene Pharma, Inc.
NSCLC
Cadonilimab Plus Chemotherapy as First-line Treatment for PD-L1 Negative NSCLC
The goal of this clinical trial is to investigate the efficacy, safety and tolerability of PD-1/CTLA-4 inhibitor (Cadonilimab) combination with chemotherapy as first-line treatment for PD-L1 negative advanced non small cell lung…
- Trial name
- LungCadX (NCT06424821)
- Testing
- Cadonilimab
- Where
- 2 sites in China
- Volunteers
- 54 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
Carcinoma, Non-Small-Cell Lung, Metastatic Lung Non-Small Cell Carcinoma
Palliative RadIotherapy of Multiple Metastatic Sites Before First Line of Systemic Therapy With Immune Checkpoint Inhibitors and Chemotherapy in Metastatic Non-Small-Cell Lung Cancer
The study is designed as a non-randomized Phase 2 clinical intervention study. The study will include patients with disseminated Non-Small Cell Lung Carcinoma (NSCLC) which are eligible for first line of systemic treatment with…
- Conditions
- Carcinoma, Non-Small-Cell Lung, Metastatic Lung Non-Small Cell Carcinoma, Non Small Cell Lung Cancer
- Trial name
- PRIMM (NCT05440916)
- Testing
- Palliative Radiotherapy: 5 x 4Gy, chemotherapy + immune checkpoint inhibitors
- Where
- 3 sites in Slovenia
- Volunteers
- 50 people
- Sponsor
- University Medical Centre Maribor
Metastatic Melanoma
Bevacizumab, Dacarbazine and Interferon-Alfa to Treat Metastatic Melanoma
The purpose of this study is to determine whether combination therapy with bevacizumab (Avastin), dacarbazine and interferon-alfa-2a (Roferon-A) is effective in patients with locally advancing or metastatic melanoma.
- Trial name
- NCT00308607
- Testing
- Bevacizumab (Avastin), dacarbazine, interferon-alfa-2a (Roferon-A)
- Where
- 3 sites in Finland
- Volunteers
- 27 people
- Sponsor
- University of Turku
HELICOBACTER PYLORI INFECTIONS
Comparison of the Efficacies of Two Novel Dose Dual Therapies in the First-line Helicobacter Pylori Eradication
Background: The key factors for success are the maintenance of intragastric pH > 6 and the drug resistance to antibiotics. Proton pump inhibitor (PPI)-based high-dose dual therapy is a novel anti-Helicobacter pylori (H.
- Trial name
- Helicobacter (NCT06811207)
- Testing
- Vonoprazan, Esomeprazole 40mg, Amoxicillin
- Where
- Taiwan
- Volunteers
- 300 people
- Sponsor
- Chang Gung Memorial Hospital
Carcinoma, Non-Small-Cell Lung, Lung Neoplasms
Osimertinib With Chemotherapy as First-line Therapy for EGFR Mutation-positive NSCLC
To estimate parameters related to clinical outcomes in a real-world seeting, including investigator reported PFS and OS .
- Conditions
- Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Respiratory Tract Neoplasms, Thoracic Neoplasms
- Trial name
- FOREFRONT (NCT06376084)
- Where
- China
- Volunteers
- 532 people
- Sponsor
- AstraZeneca
Triple Negative Breast Cancer
A Study of SYS6043 Versus Investigator's Choice Chemotherapy as First-Line Treatment in Patients With Unresectable Locally Recurrent or Metastatic Triple-Negative Breast Cancer
This is a randomized, controlled, open-label, multicenter study. Eligible participants are patients with unresectable locally recurrent or metastatic triple-negative breast cancer (TNBC) who have not received prior systemic…
- Trial name
- NCT07879911
- Testing
- Enter a brief, descriptive name for the intervention. Use a non-proprietary (generic) name, if available. SYS6043, Investigator's Choice of Chemotherapy (paclitaxel，nab paclitaxel，capecitabine，eribulin，carboplatin）
- Volunteers
- 550 people
- Sponsor
- CSPC Megalith Biopharmaceutical Co.,Ltd.
Leukemia, Lymphocytic, Chronic, B-Cell
A Study to Assess the Efficacy of Rituximab (MabThera) in First Line Treatment of Chronic Lymphocytic Leukemia (CLL)
This single arm study will assess the efficacy and safety of rituximab in combination with fludarabine and cyclophosphamide, followed by rituximab maintenance therapy, as first line treatment of participants with CLL.
- Trial name
- NCT00545714
- Testing
- Cyclophosphamide, Fludarabine, Rituximab
- Where
- 33 sites in Spain
- Volunteers
- 86 people
- Sponsor
- Hoffmann-La Roche
MPM
A Study of PM8002 Injection in Combination With Standard Chemotherapy as First Line Therapy in MPM
PM8002 is a bispecific antibody targeting PD-L1 and VEGF. This study will evaluate the efficacy and safety of PM8002 in combination with pemetrexed and platinum as first line treatment for MPM.
- Trial name
- NCT05918107
- Testing
- PM8002, Pemetrexed, Cisplatin
- Where
- 16 sites in China
- Volunteers
- 31 people
- Sponsor
- Biotheus Inc.
Metastatic Colorectal Cancer
Cetuximab and Envafolimab Plus mFOLFOXIRI as First-line Treatment for RAS/BRAF Wild-type, MSS, Unresectable Left-side Metastatic Colorectal Cancer
The primary aim of phase II CEIL study is to evaluate the efficacy of cetuximab and envafolimab plus mFOLFOXIRI versus cetuximab plus mFOLFOX6 as first line treatment of patients with initially unresectable and previously…
- Trial name
- CEIL (NCT05959356)
- Testing
- Cetuximab + Envafolimab + mFOLFOXIRI, Cetuximab + mFOLFOX6
- Where
- 3 sites in China
- Volunteers
- 198 people
- Sponsor
- Sun Yat-sen University
Pancreatic Adenocarcinoma Metastatic
Penpulimab Combined With Anlotinib and Nab-paclitaxel Plus Gemcitabine as First-line Treatment for Advanced Metastatic Pancreatic Cancer
This is a multi-center, open-label， randomized controlled Phase II clinical study to observe and evaluate the efficacy and safety of Penpulimab combined with Anlotinib and Nab-paclitaxel plus Gemcitabine (PAAG ) versus AG…
- Trial name
- RCT-PAAG (NCT06051851)
- Testing
- Penpulimab, Anlotinib, Nab paclitaxel
- Where
- China
- Volunteers
- 177 people, healthy volunteers welcome
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Paroxysmal Atrial Fibrillation
Safety and Efficacy of Cryoballoon Ablation of Atrial Fibrillation as First-line Therapy
Cryoballoon ablation of paroxysmal atrial fibrillation can be used as first-line therapy compared to second choice after failed medical therapy
- Trial name
- C-frost (NCT01920295)
- Testing
- Cryoballoon ablation
- Where
- Turkey (Türkiye)
- Volunteers
- 60 people
- Sponsor
- Yuksek Ihtisas Hospital
Peritoneal Metastases, Gastric Cancer
HIPEC Combined With SOX and Sintilimab in the Treatment of Advanced Gastric Cancer With Peritoneal Metastasis
The prognosis of patients with peritoneal metastasis from gastric cancer is extremely poor. Although chemotherapy combined with immunotherapy has achieved promising efficacy in the first-line treatment of advanced gastric cancer…
- Trial name
- NCT06213519
- Testing
- S-1, Oxaliplatin sintilimab HIPEC
- Volunteers
- 69 people
- Sponsor
- Sichuan University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.